Research programme: antibody-drug congugate therapeutics - CytomX TherapeuticsAlternative Names: Integrin alpha 3 Probody™-drug conjugate - CytomX Therapeutics; ITGA3 PDC - CytomX Therapeutics
Latest Information Update: 19 Dec 2016
At a glance
- Originator CytomX Therapeutics
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Integrin alpha chain inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 19 Dec 2016 Early research in Cancer in USA (Parenteral)